Lasa Supergenerics growth ratios

·Pharma & HealthChart ›
ProfitabilityGrowthCreditLiquidityWorking capitalDividend yieldDuPontCAGR
Per cent unless marked ×
Tap a line for its trendFY26Mar 2026FY25Mar 2025FY24Mar 2024FY22 and earlierAlpha Plus
−82.4%+36.5%−19.5%
FY22 and earlierEvery year the company has filed comes with Alpha Plus.
−553.3%+189.3%+132.8%
−470.5%+29.1%+57.5%
−131.0%+32.1%+43.7%
−130.5%+32.0%+71.9%
−34.7%−32.7%−7.9%
−40.7%−13.4%−18.3%
−708.4%−232.1%+106.4%
Open the chart

From the company's filings with NSE and BSE (Ind-AS), standalone. For information only, not investment advice.

LASA₹4.67

Lasa Supergenerics Limited

· Pharma & Health
₹ CrorePeersMANGALAMBIOFILCHEMORTINGLOBEVINEETLABKREBSBIOALPABALPHARMANATCAPSUQMcap ₹23.4 Cr
ProfitabilityGrowthCreditLiquidityWorking CapitalYield AnalysisDuPont
Ratios — % unless marked ×
12 Months Ending
FY23
31/03/2023
FY24
31/03/2024
FY25
31/03/2025
FY26
31/03/2026
Last 12M
30/06/2026
Revenue Growth—-19.5+36.5-82.4—
EBITDA Growth—+132.8+189.3-553.3—
EBIT Growth—+57.5+29.1-470.5—
Net Income Growth—+43.7+32.1-131.0—
EPS Growth—+71.9+32.0-130.5—
Total Assets Growth—-7.9-32.7-34.7—
Total Equity Growth—-18.3-13.4-40.7—
Cash from Operations Growth—+106.4-232.1-708.4—
No consensus estimates → no Est columns. Click any row to chart it.
« ‹ › »Latest: FY26 · StandaloneFA Financial Analysis · alphave
Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreement — XBRL cross-verified ✓ 95%.